Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells
Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells Spadaro et al. JNI; August 2015 Background The purpose of this research was to validate the low expression The following content is accessible for members only, please sign in.